In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has aggressively blocked competition for it. By Rebecca Robbins With a sticker price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback